Recent clinical trials with gene expression profiling of psoriasis skin revealed promising data supporting the hypothesis that a monoclonal blockade of pathogenic T-cells, such as an IL-17A blockade or an IL-23p19 blockade, may induce expansion of regulatory immune cells subsets or expression of cytokines involved in skin homeostasis (42–44). The gene discussed is IL23A; the disease is psoriasis.